Cyclophosphamide and cisplatin VS pacltitaxel and cisplatin in patients with advanced-stages ovarian carcinoma

ABSTRACT

Treatment plan Sixty women refered to Oncology Department, Zagazig University Hospitals and Alexandria university Hospital with stages III and IV ovarian cancer and with measurable disease at least one centimeter as a residual after any surgical procedure. Thirty patients in the historical standard-therapy group [group A] were previously received cyclophosphamide [750mg/rn2 I. V] and cisplatin [75 mg/m2 I. V. infusion] every three weeks for a total of six cycles. Data were collected from files and from survived patients under follow up. Thirty patients in the experimental group [group B] received paclitexel [135 mg/m2 I. V. infusion over a period of three hours] and cisplatin [75mg/m2 I. V infusion] every three weeks for a total of six cycles. The overall response rate 83.4% was in group "B" versus 66.7% in group "A" [P.>0.05] Complete clinical responses were more frequent among women in group "B" [56.7%] than among those in group "A" [26.7%] P.>0.05. Seven women out of 17 [41.2%] in group "B" showed negative pathological results after laparotomy versus 2 out of 8 [25%] in group "A The overall survival rate was found to be 46.7% in group "A" versus 63.3% in group "B" with a median follow-up period of 28 months and 26 months respectively [P>0.05]. The progression-free survival in the same periods was 13.3% in group "A" versus 36.7% in group "B" [P<0.05]. Paclitaxel and cisplatin used as a first line therapy improves complete clinical response, overall survival, and progression-free survival rates in women with advanced stages [III and VI] ovarian cancer who have neasurable residual masses